I-Mab (NASDAQ:IMAB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Friday, Benzinga reports. They currently have a $6.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 231.49% from the stock’s previous […]
By Rob Curran Biotech concern I-Mab agreed to sell its Chinese unit to affiliate I-Mab Biopharma (Hangzhou)for up to $80 million after contingencies, and it.
I-Mab (NASDAQ:IMAB – Get Free Report) and Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 22.6% of I-Mab shares are […]
Cantor Fitzgerald restated their overweight rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for I-Mab’s FY2023 earnings at ($1.85) EPS and FY2024 earnings at ($1.14) EPS. Separately, Needham & Company LLC dropped their price target on shares of […]
I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy o